Preeclampsia
Conditions
Keywords
innate immunity, macrophage, toll-like receptors, trophoblasts, phagocytos
Brief summary
Introduction: The etiology/pathophysiology of preeclampsia remains an enigma. Cellular immunity is a key factor in the etiology of late-onset preeclampsia (L-PrE). Presepsin is split out from the phagocytes membranes after phagocytosis. To investigators knowledge, this is the first study in literature to investigate maternal blood concentrations of presepsin in preeclampsia and healthy pregnant women. Methods: The investigators examined maternal plasma interleukin-6, presepsin and pentraxin-3 concentrations in pregnant women with (n=44) and without L-PrE (n=44). These three inflammatory markers concentrations measured using enzyme-linked immunosorbent assays were compared.
Detailed description
This observational case-control study was designed at Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey, in the Department of Obstetrics and Gynecology between June 2018 and January 2019. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (Reference number: 2018/393). The study strictly adhered to the principles of the Declaration of Helsinki. All subjects included in the study gave oral and written informed consent. Eighty-eight women were enrolled in the study in two groups. All participants will gave their oral and written informed consent before their inclusion in the study.
Interventions
OTHERinterleukin-6, presepsin and pentraxin-3
measurements and compare
Sponsors
Cengiz Gokcek Women's and Children's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* preeclampsia healthy pregnancy
Exclusion criteria
1. pregnant women with any systemic condition (such as chronic hypertension, inflammatory and rheumatic diseases), 2. using any kind of medication throughout pregnancy (such as acetylsalicylic acid, corticosteroids or heparin), 3. pregnant women who had fever at the time of the first admission, 4. concurrent infections (urinary tract infection, cervicitis, etc.), 5. pregnancies complicated with premature membrane rupture or chorioamnionitis, 6. history of medication for PE treatment at the time of the first admission, 7. patients who had fetal congenital abnormalities or genetic syndromes, 8. drug user, 9. multiple gestations, 10. active labor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary endpoint in these analyses was IL-6, presepsin and pentraxin-3 levels in late-onset preeclampsia group and control group. | 3 months | The primary endpoint in these analyses was IL-6, presepsin and pentraxin-3 levels in late-onset preeclampsia and control group. |
Countries
Turkey (Türkiye)
Outcome results
None listed